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The repositioning of approved drugs is atopic of interest for the academy and the pharmaceutical 
industry. The synergistic combination of these drugs can be successful in the treatment of infections 
caused by resistant bacteria. This study aimed to assess the in vitro synergistic antibacterial activity of 
sertraline and disulfiram and their interaction with ciprofloxacin and sulfamethoxazole/trimethoprim. 
We determined the minimum inhibitory concentration, the minimum bactericidal concentration and the 
fractional inhibitory concentration index. Eighteen bacterial strains were used, being nine American Type 
Culture Collection reference strains and nine multidrug resistant clinical isolates. Synergy was detected 
between sertraline and disulfiram against a strain of Staphylococcus aureusATCC 25923 and a clinical 
isolate of S. aureus. When associated to sulfamethoxazole/trimethoprim and ciprofloxacin, sertraline and 
disulfiram showed eight synergistic events, which occurred against three different standard strains and 
two multidrug resistant clinical isolates. When the minimum bactericidal concentration was determined, 
the bactericidal activity of sertraline was enhanced with disulfiram. Our results suggest that these drugs, 
widely used to treat depression and chronic alcoholism, have antibacterial potential individually, in 
association, and combined with antimicrobials, what makes their repositioning a promising therapeutic 
alternative for the effective treatment of infections caused by multidrug resistant bacteria.
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INTRODUCTION
The indiscriminate use of antimicrobials in clinical 
therapy has triggered the emergence of multidrug 
resistant bacteria (MDR) (Dos Santos, La Rocca, Hörner, 
2016), what represents a serious problem for public 
health worldwide since the therapeutic alternatives for 
treatments have become limited (Franco, Menezes, 
Cabral, 2015).
Although there is an increasing need for active 
compounds against MDR bacteria, research for new drugs 
has not evolved in line with the demand, and alternative 
measures are necessary for the control of infectious 
diseases (Grillo etal., 2014). Therefore, new therapies 
can emerge through drug repositioning with drugs that 
are already used clinically and whose tests with patients 
are known (Wiggins et al., 2015). In addition, there 
can be synergistic combinations between these drugs, 
contributing to a more effective treatment (Zheng, Sun, 
Simeonov, 2017).
Ashburn and Thor (2004) defined drug repositioning 
as the process of finding a new indication for a drug 
which has already been approved. This method has 
proved to be the preferred alternative strategy for the 
fast-moving discovery of drugs, since it is relatively 
cheaper and represents a minimum risk to patients due to 
the availability of previous pharmacological, safety and 
toxicological data (Mehndiratta et al., 2016).
In light of this, repositioning is an attractive approach 
for studies that investigate the antimicrobial activities 
of psychotropics, local anaesthetics, tranquilizers, 
as well as cardiovascular, anti-histaminic and anti-
inflammatory drugs (Chan et al., 2017; Mandal et al., 
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2010; Rampelotto et al., 2018). The combination of drugs 
has been successfully used to treat MDR bacteria due to 
the synergistic effect achieved by the aggregation of their 
different action mechanisms. Thus, a fast identification 
of therapies to treat acute infections also emerges with 
the combination of repositioned synergistic drugs, 
outweighing the problem of weak drug activity when used 
individually (Zheng, Sun, Simeonov, 2017).
Thus, this study assessed the in vitro antibacterial 
activity of sertraline and disulfiram, the synergy of their 
combination and the combination with the antimicrobials 
ciprofloxacin and sulfamethoxazole/trimethoprim. The 
tests were performed through the determination of the 
minimum inhibitory concentration (MIC),minimum 
bactericidal concentration (MBC), and the assessment of 
the fractional inhibitory concentration index (FICI).
MATERIAL AND METHODS
Bacterial strains
Eighteen bacterial strains were used, including nine 
American Type Culture Collection (ATCC) reference strains 
(Staphylococcus aureus ATCC 25923, Staphylococcus 
aureus ATCC 29213, Enterococcus faecalis ATCC 29212, 
Micrococcus luteus ATCC 7468, Bacillus cereus 
ATCC 14579, Escherichia coli ATCC 35218, Escherichia 
coli ATCC 25922, Klebsiella pneumoniae ATCC 700603 
and Pseudomonas aeruginosa ATCC 27853), and 
nine MDR clinical isolates from patients at Hospital 
Universitário de Santa Maria (HUSM): four isolates of 
S. aureus, and one isolate of each of the following species: 
S. warneri, S. haemolyticus, S. epidermidis, P. aeruginosa 
and A. baumannii.
The clinical isolates were identified with the 
automated system Vitek® 2 (bioMérieux, France). For 
the characterization of MDR bacteria, the guidelines of 
the Technical Note n. 1/2010 from the Brazilian National 
Health Surveillance Agency (ANVISA) (Anvisa, 2010) 
were followed. According to these guidelines, MDR 
bacteria are microorganisms resistant to different classes of 
antimicrobials tested in microbiological control tests.The 
use of these isolates for clinical research was approved by 
the Research Ethics Committee of Universidade Federal 
de Santa Maria (UFSM) under the protocol number: 
38850614.4.0000.5346.
Drugs used
Sertraline (Legrand Pharma Indústria Farmacêutica 
Ltda., Hortolândia, SP, Brazil), disulfiram (Sanofi-Aventis 
Farmacêutica Ltda., São Paulo, SP, Brazil), ciprofloxacin 
(Cimed Indústria de medicamentos Ltda, Pouso Alegre, 
MG, Brazil) and sulfamethoxazole/trimethoprim 
(Produtos Roche Químicos e Farmacêuticos S. A., Rio 
de Janeiro, RJ, Brazil) were tested against all the above-
cited strains. To obtain the stock solution of sertraline, 
ciprofloxacin and sulfamethoxazole/trimethoprim, they 
were dissolved in absolute methanol, and disulfiram was 
dissolved in absolute ethanol.The tested concentration 
for these drugs was 0.5-512 µg mL-1. In order to confirm 
the inexistence of inhibitory activity of solvents, 10% 
methanol and ethanol were used in a test performed 
separately. 
Antibacterial and susceptibility tests
Minimum inhibitory concentration (MIC) determinations
MIC was determined through the standard method 
of broth microdilution according to the Clinical and 
Laboratory Standards Institute (CLSI, 2012). Tests were 
run in triplicate, with reports being visually performed 
after 24 hours of incubation at 35 ± 2 °C. The bacterial 
inoculum was prepared in a sterile saline solution, with 
concentration of bacterial suspension following the 
0.5 McFarland scale, which is 1.5 x 108 colony forming 
units/mL (UFC/mL).
Minimum bactericidal concentration (MBC) 
determinations
MBC was performed according to the method 
described in the document M26-A from the National 
Committee for Clinical Laboratory Standards (NCCLS) 
(NCCLS, 1999), with adaptations. After the visual reading 
of MIC, approximately 10 μL of the content from the 
pits where there was no visible bacterial growth were 
removed, as well as from the last pit, with visible bacterial 
growth. This volume was stocked in petri dishes with 
Mueller-Hinton agar, and incubated at 35 ± 2 °C for 48 
h. After incubation, MBC was determined as the smallest 
concentration in which no microorganism growth was 
observed.
Fractioned inhibitory concentration index (FICI) 
determinations
Synergism analysis of the two drugs was obtained 
by calculating the fractioned inhibitory concentration 
index (FICI), whose interpretation can be classified as 
“synergistic” (FIC≤0,5), “non-interactive” (FIC > 0.5 e 
≤ 4.0) and “antagonistic” (FIC > 4.0) (Konaté et al., 2012; 
Odds, 2003).
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RESULTS AND DISCUSSION
MIC and FICI values obtained can be seen in Table I. 
Results show that disulfiram was particularly more active 
against standard Gram-positive strains, whereas sertraline 
showed activity against both standard Gram-positive and 
Gram-negative strains. When their activity was tested 
against clinical isolates, sertraline showed strong activity 
against five isolates of Staphylococcus (MIC=8 µg.mL-1). 
When combined, sertraline and disulfiram showed a 
synergistic effect against Staphylococcus aureus ATCC 
25923 and the isolate S. aureus MDR (1) (MIC = 4 µg mL-1; 
FICI=0 5).
Regarding the interaction of these two drugs with 
conventional antimicrobials, the synergy of sertraline 
and disulfiram with sulfamethoxazole/trimethoprim was 
observed against the strain of E. coli ATCC 35218. When 
associated to ciprofloxacin, they showed synergy against 
B. cereus.Also, the combination of ciprofloxacin with 
disulfiram was effective against the strain of M. luteus and 
the clinical isolate A. baumannii, where as the interaction 
of disulfiram with sulfamethoxazole/trimethoprim 
showed synergy against the isolates P. aeruginosa and 
A. baumannii.
Munoz-Bellido, Munoz-Criado and García-
Rodríguez (2000) assessed the antibacterial activity of 
sertraline in different clinical isolates from patients at 
Hospital Universitario de Salamanca, Spain. The values 
of MIC 90 obtained against S. aureus (MIC = 16 µg.mL-1) 
and S. epidermidis (MIC = 16 µg.mL-1), were similar 
to the ones found in this study, however, the values 
of A. baumanii  (MIC = 64 µg.mL -1)  and E. coli 
(MIC = 128 µg.mL-1) were higher than those found in our 
study.
Philips et al. (1991) obtained MIC = 1,33 µg.mL-1for 
all the investigated isolates while investigating the in vitro 
activity of disulfiram against S. aureus in Valhalla, New 
York. In the present study, we found MIC values higher 
than those reported by that research group. This fact may 
be related to the differences of the raw material used and 
its dissolution, and the different clinical isolates. However, 
when associating sertraline and disulfiram, we observed 
TABLE I – Minimum inhibitory concentrations (MIC) of the sertraline,  disulfiram, sulfamethoxazole/trimethoprim and ciprofloxacin, 
alone and in combination against standard strains and clinical isolates
Bacterial strain MIC (µg mL-1)









Staphylococcus aureus ATCC 29213 32 >512 32 - 1 1 1.03 1 - 4 4 1.125 4 -
Staphylococcus aureus ATCC 25923 16 16 4 0.5 256 16 1.06 16 1.06 256 16 1.06 16 1.06
Enterococcus faecalis ATCC 29212 16 16 8 1 1 0,5 0,53 0,5 0,53 1 0,5 0,53 0,5 0,53
Micrococcus luteus ATCC 7468 16 32 8 0.75 256 32 2.125 32 1.125 64 8 0.625 4 0.18
Bacillus cereus ATCC 14579 32 8 4 0,62 32 32 2 4 0.625 2 0,25 0.13 0,25 0.15
Escherichia coli ATCC 35218 32 256 16 0.56 8 1 0.15 1 0.12 1 2 2.06 2 2.00
Escherichia coli ATCC 25922 32 >512 32 - 1 0,5 0.51 0,5 - 0,25 0,25 1,0 0,25 -
Klebsiella pneumoniae ATCC 700603 16 >512 32 - 4 4 1.25 16 - 0,5 0,25 0.51 0,25 -
Pseudomonas aeruginosa ATCC 27853 >512 >512 >512 - 256 128 - 64 - 1 0,25 - 0,25 -
Clinical isolates
Staphylococcus aureus MDR (1) 16 16 4 0.5 256 16 1.06 32 2.125 64 8 0.625 32 2.5
Staphylococcus aureus MDR (2) 16 16 16 2 256 16 1.06 16 1.06 64 32 2.5 16 1.25
Staphylococcus aureus MDR (3) 8 4 4 1.5 128 8 1.06 8 2.06 128 16 2.06 16 2.12
Staphylococcus aureus MDR (4) 8 16 16 3 512 16 2.03 16 1,03 256 16 2.06 16 1,06
Staphylococcus warneri MDR 8 16 4 0.75 512 512 8 256 1.01 512 16 1.03 16 2.03
Staphylococcus haemolyticus MDR 8 8 4 1 256 16 2.06 16 2.06 128 16 2.12 16 2.12
Staphylococcus epidermidis MDR 8 16 8 1.5 16 16 3 8 1 2 2 1.25 2 1.12
Pseudomonas aeruginosa MDR 16 512 32 2.06 128 32 2.25 32 0.31 1 1 1.06 1 1
Acinetobacter baumannii oxa 23 MDR 16 128 16 1.125 256 32 2.12 16 0,18 32 32 3 8 0,31
SER, sertraline; DSF, disulfiram; SER+ DSF, combination of sertraline and disulfiram; SUT, sulfamethoxazole/trimethoprim; SUT+ SER, combination of 
sulfamethoxazole/trimethoprim and sertraline; SUT +DSF, combination of sulfamethoxazole/trimethoprim and disulfiram; CIP, ciprofloxacin; CIP+SER, 
combination of ciprofloxacin and sertraline; CIP+DSF, combination of ciprofloxacin and disulfiram; FICI, Fractional Inhibitory Concentration Index; (-), result 
without determination; MDR, multidrug-resistant bacteria. *,5 times the concentration of trimethoprim.
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that such combination was able to inhibit the growth of 
the MDRS. aureus, with FICI = 0.5, what characterizes a 
synergistic effect between these drugs.
Studies that assess the synergistic antibacterial 
activity of potential candidates for drug repositioning 
are already being explored, such as the one developed 
by Chan et al. (2017) in Malaysia. These researchers 
have assessed the synergistic antibacterial activity of 
the non-steroidal anti-inflammatory drugs cefuroxime 
and chloramphenicol against methicillin-resistant and 
methicillin-susceptible S. aureus; however, MICs were 
evaluated in mg.mL-1, and their concentrations were 
around one thousand times higher than the ones in the 
current study.
The antibacterial mechanisms of action of sertraline 
and disulfiram have not yet been established. However, 
Munoz-Bellido, Munoz-Criado, and García-Rodríguez 
have suggested that the action of sertraline occurs through 
the inhibition of efflux pumps, since it is a consensus that 
this drug acts in human cells as an inhibitor of these pumps 
(Munoz-Bellido, Munoz-Criado, Garcìa-Rodrìguez, 
2000).
Disulfiram, on the other hand, shows several 
mechanisms capable of inhibiting bacterial growth. Its 
main metabolite is diethyldithiocarbamate (DDTC). This 
drug is probably metabolized by the bacteria in order to 
form DDTC, which has antibacterial effects (Horita et al., 
2009; Horita et al., 2012; Takii et al., 2012). In addition, 
Cvek (2013) has observed that disulfiram is able to exert 
proteolytic activity through ion chelation, what may cause 
bacterial inhibition.
The MBC determination of sertraline and disulfiram 
is described in Table II. Through these data, we can 
infer that sertraline individually showed bactericidal 
activity against most tested strains, whereas disulfiram 
did not exert this activity. However, when we associated 
these drugs, the activity of sertraline was intensified, 
especially against Staphylococcus aureus ATCC 25923, 
Enterococcus faecalis ATCC 29212, Escherichia coli 
ATCC 35218 and Bacillus cereus ATCC 14579. As for 
TABLE II – Minimum bactericide concentrations (MBC) of the sertraline and the disulfiram, sulfamethoxazole/trimethoprim and 
ciprofloxacin, alone and in combination against standard strains and clinical isolates
Bacterial strain MBC (µg mL-1)









Staphylococcus aureus ATCC 29213 32 - 64 >512 128 >512 >512 >512 >512
Staphylococcus aureus ATCC 25923 32 >512 16 >512 256 >512 >512 >512 >512
Enterococcus faecalis ATCC 29212 32 >512 16 >512 128 >512 >512 >512 >512
Micrococcus luteus ATCC 7468 16 >512 16 >512 128 >512 >512 256 >512
Bacillus cereus ATCC 14579 64 32 4 >512 128 >512 1 1 1
Escherichia coli ATCC 35218 256 >512 32 >512 >512 >512 >512 128 >512
Escherichia coli ATCC 25922 64 >512 64 >512 128 >512 2 2 2
Klebsiella pneumoniae ATCC 700603 32 >512 64 >512 128 >512 1 1 1
Pseudomonas aeruginosa ATCC 27853 >512 >512 >512 256 256 >512 1 1 1
Clinical isolates
Staphylococcus aureus MDR (1) 512 >512 64 >512 >512 >512 >512 128 >512
Staphylococcus aureus MDR (2) 64 >512 64 >512 128 >512 >512 256 >512
Staphylococcus aureus MDR (3) 32 >512 32 >512 128 >512 128 128 128
Staphylococcus aureus MDR (4) 128 >512 32 >512 256 >512 >512 256 >512
Staphylococcus warneri MDR >512 >512 8 >512 >512 >512 >512 >512 >512
Staphylococcus haemolyticus MDR 64 >512 16 >512 128 >512 >512 128 >512
Staphylococcus epidermidis MDR 16 >512 32 >512 64 512 2 2 2
Pseudomonas aeruginosa MDR >512 >512 >512 128 512 >512 512 512 512
Acinetobacter baumanni oxa 23 MDR 32 >512 16 >512 64 >512 >512 64 512
SER, sertraline; DSF, sisulfiram; SER+ DSF, combination of sertraline and disulfiram; SUT, sulfamethoxazole/trimethoprim; SUT+ SER, 
combination of sulfamethoxazole/trimethoprim and sertraline; SUT +DSF, combination of sulfamethoxazole/trimethoprim and disulfiram; CIP, 
ciprofloxacin; CIP+SER, combination of ciprofloxacin and sertraline; CIP+DSF, combination of ciprofloxacin and disulfiram; (-), result without 
determination. *,5 times the concentration of trimethoprim.
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the clinical isolates, this activity was evidenced mainly in 
S. warneri (MBC = 8 µg.mL-1).
In the present study, sertraline and disulfiram 
showed a synergistic antibacterial activity against specific 
reference standard strains and MDR clinical isolates 
tested, and their interactions with sulfamethoxazole/
trimethoprim and ciprofloxacin also showed to be 
synergistic. These results allow us to suggest that their 
repositioning is a promising therapeutic alternative for the 
effective treatment of multi-resistant bacterial infections. 
Nevertheless, additional studies about the mechanisms of 
action involved in these activities are needed for the safe 
associated use of these drugs.
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